News  |  Press  |  Blog

Latest news from the Science Center, the companies we support and the innovation ecosystem.

October 28, 2019 | Resident & Alumni News

NextUp: The Local Company Discovering Targeted Therapies for Disease

Ben Doranz is a true product of University City’s innovation hub. He worked as a lab tech at the Wistar Institute before earning a Ph.D. in cell and molecular biology at the University of Pennsylvania and later an MBA from the Wharton School. So, naturally, when Doranz decided to launch his own company, Integral Molecular, in 2001, he established his first lab at the University City Science Center.

Read More
October 17, 2019 | Resident & Alumni News

Philadelphia biotech expands Science Center footprint as it adds jobs

Integral Molecular has added a 26,000-square-foot research site at 3624 Market St.

Read More
September 30, 2019 | Resident & Alumni News

NextUp: The Local Company Pioneering Personalized Medicine for Dogs

By treating canines as patients, the One Health Company wants to cure cancer in dogs and eventually in people.

Read More
May 29, 2019 | Resident & Alumni News

Amicus, Penn expand gene therapy collaboration in a big way

The expanded collaboration and licensing deal will include Amicus providing $50 million in research funding, over five years, to Penn's gene therapy program.

Read More
May 14, 2019 | Resident & Alumni News

Collaborative Makerspace Network NextFab is Celebrating Ten Years of Business in Philadelphia

Collaborative Philadelphia-based workspace NextFab isn’t just made up of one location, but is actually a regional network of makerspaces and business incubators, where artisans, hardware entrepreneurs, and makers can feel free to come in and work on their latest projects

Read More
May 14, 2019 | Resident & Alumni News

Business for Good: iBreastExam

When computer engineer Mihir Shah was about to get married in 2007, the joyful occasion was overshadowed by a shock: His mother-in-law was diagnosed with breast cancer, had to undergo chemotherapy, and attended the wedding covering her head with a wig. The experience motivated 41-year-old Shah to research breast cancer treatments, and he was surprised to realize that the survival rates of women with breast cancer largely depend on one factor: where they live.

Read More
April 16, 2019 | Resident & Alumni News

Integral Molecular Doubles Antibody Characterization Capacity Within Philadelphia's Science Center

Integral Molecular, the industry leader in membrane protein solutions, today announced the expansion of its two proprietary antibody characterization platforms, Shotgun Mutagenesis Epitope Mapping and the Membrane Proteome Array (MPA). Integral Molecular recently acquired office and laboratory space, which enabled the company to double its antibody characterization capabilities.

Read More
March 19, 2019 | Resident & Alumni News

Winners of the second annual Lyfebulb-Helsinn Innovation Summit & Awards in Oncology announced

Lyfebulb, a patient-empowerment platform that connects patients with industry to support user-driven innovation, and Helsinn, a Swiss pharmaceutical group focused on building quality cancer care, today announced that Mihir Shah of UE LifeSciences and Pierluigi Paracchi of Genenta Science were chosen as winners of the second Lyfebulb-Helsinn Innovation Summit and Awards in Oncology. Mihir received the Lyfebulb-Helsinn Innovation Award, and Pierluigi received The Squinto-LePera award, which was presented by Dr. Stephen Squinto and Denise LePera. The awards recognize outstanding innovations by Patient Entrepreneurs which advance solutions in the prevention, management or care of cancer, and have the potential to be commercialized.

Read More
March 12, 2019 | Resident & Alumni News

Oncoceutics licenses rights for its anti-cancer compound to Ohara

US based Oncoceutics, Inc. has announced the outlicense of the rights to the company’s lead compound, ONC201, for Japan to Ohara Pharmaceutical Co., Ltd. In addition, Ohara will receive a right of first refusal on the license of ONC201 for additional areas, including most of Asia and West Africa, and a right of first refusal for the company’s next generation compound, ONC206, in these territories.

Read More
March 1, 2019 | Resident & Alumni News

Spark Therapeutics’ $4.8B deal confirmed as biggest-ever VC-backed exit in Philly

The eye-popping $4.8 billion sticker price on Spark Therapeutics’ acquisition deal with Roche announced on Monday is shaping up to be the largest exit ever within city limits for a venture-backed company, according to data from financial data provider PitchBook and the Philadelphia Alliance for Capital and Technologies (PACT).

Read More

Sign up to receive email updates from Flying Slippers!

Kristen Fitch

Director, Marketing

kfitch [at]